|
March 21, 2007 08:00 AM Eastern Daylight Time
TransPharma Medical Named Winner of 2007 Red Herring 100 Europe Award
LOD, Israel--(BUSINESS WIRE)--TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today that it has been selected as a recipient of Red Herring 100 Europe, an award given to the top 100 private technology companies based in the EMEA (Europe, Middle East and Africa) region each year.
“It is an honor to have been recognized by Red Herring as one of the top 100 private technology companies in our region,” said Dr. Daphna Heffetz, Chief Executive Officer of TransPharma Medical. “The Red Herring 100 Europe is an endorsement of our breakthrough RF-MicroChannel technology for transdermal drug delivery. The first two drug products based on our technology are a proprietary transdermal hPTH (1-34) product to treat osteoporosis and a transdermal hGH product to treat growth hormone deficiency, which we are developing in collaboration with Teva Pharmaceutical Industries. Both these products are currently in phase I/II clinical trials, and we are encouraged by promising initial results.”
Red Herring’s lists of top private companies are an important part of Red Herring’s tradition of identifying new and innovative technology companies and entrepreneurs. Companies like Google, eBay and Skype were spotted in their early days by Red Herring editors, and touted as leaders that would change the way we live and work.
“This year’s impressive list of winners demonstrates Europe’s emergence as a major player in the global technology sector,” said Red Herring Editor-in-Chief, Joel Dreyfuss. “The exceptional accomplishments of European technology companies and entrepreneurs are a testament to the rapid advancements being made in building the European innovation ecosystem.”
Red Herring’s editorial staff rigorously evaluated more than 700 private companies through a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development.
As one of the winners, Dr. Daphna Heffetz, TransPharma Medical’s CEO, will present the company at Red Herring’s Venture Market Europe (VME) 2007 event, scheduled for March 25-27, at the Intercontinental Carlton in Cannes, France.
About TransPharma Medical
Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology. Providing an easy-to-use, cost-effective, at-home solution, TransPharma’s ViaDerm drug delivery system enables the delivery of a wide variety of product candidates, including hydrophilic small molecules, peptides and proteins. TransPharma aims to develop multiple drug products through strategic partnerships with leading pharmaceutical companies and through independent product development. For more information, visit the Company's website at www.transpharma-medical.com.
About Red Herring
Red Herring is a global media company which unites the world’s best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider’s access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available on the Internet at www.redherring.com.
|
